This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy…
QED
December 20, 2019
QED Achondroplasia Clinical Update
QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (“BridgeBio”) focuses on bringing medicine to people living…
Established in 2018, The Chandler Project provides advocacy, awareness, research and support to those affected by achondroplasia, the most common form of dwarfism, and other skeletal dysplasias. TCP hosts the only event in North Amercia that brings together members of the skeletal dysplasia community physicians, researchers, biotech industries and more together at the annual Achondroplasia + Skeletal Dysplasia Research Conference.